MIM
BOLD

MetLife Investment Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

MetLife Investment Management’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-19,977
Closed -$1.2M – 2364
2019
Q4 		$1.2M Hold
19,977
– – 0.01% 1009
2019
Q3 		$561K Hold
19,977
– – 0.01% 1356
2019
Q2 		$756K Buy
19,977
+2,834
+17% +$109K 0.01% 1249
2019
Q1 		$669K Hold
17,143
– – 0.01% 1284
2018
Q4 		$365K Buy
17,143
+2,154
+14% +$55.6K ﹤0.01% 1552
2018
Q3 		$593K Hold
14,989
– – 0.01% 1425
2018
Q2 		$573K Buy
14,989
+7,059
+89% +$261K 0.01% 1331
2018
Q1 		$238K Hold
7,930
– – ﹤0.01% 1796
2017
Q4 		$248K Buy
+7,930
New +$218K ﹤0.01% 1816

MetLife Investment Management's BOLD Position: Q1 2020 in Review

MetLife Investment Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 19,977 shares — an estimated $1.2M sold.

MetLife Investment Management first reported a position in BOLD in Q4 2017 and held it in 9 quarters. The position peaked at $1.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • MetLife Investment Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • MetLife Investment Management sold 19,977 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $1.2M.
  • MetLife Investment Management first reported a position in Audentes Therapeutics, Inc in Q4 2017 and held it in 9 quarters.
  • MetLife Investment Management's Audentes Therapeutics, Inc position peaked at $1.2M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on MetLife Investment Management's 13F filing for Q1 2020, filed 15 May 2020.